Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage

Table 1 Comparison of underlying disease, the effect of intrapulmonary rFVIIa therapy, and survival of DAH

Patient	Gender	Diagnosis	Pathogenesis of DAH	rFVIIa doses via BAL	Evaluation of rFVIIa effect^a	Survival or cause of death
1	Male	Allo-HSCT^b (CLL)	CMV, GvHD	3	Good	Septic shock and cardiorespiratory failure
2	Male	Neurosarcoidosis	Unknown	1	Excellent	Septic shock
3	Male	AML	Unknown	1	Excellent	Survived
4	Female	Wegener's granulomatosis	Unknown	1^c	Good	Survived
5	Female	AIDS	Unknown	2	Good	Septic shock and respiratory failure
6	Male	Allo-HSCT (AML)	Unknown	1	Excellent	Survived

^aThe hemostatic effect was statistically significant (p = 0.031, McNemar's test). ^bNon-myeloablative allogeneic stem cell transplantation. ^cOne rFVIIa dose via BAL and, three days later when not intubated, subsequent three consecutive doses of rFVIIa via jet nebulizer. AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; CLL, chronic lymphatic leukemia; CMV, cytomegalovirus; DAH, diffuse alveolar hemorrhage; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; rFVIIa, human recombinant activated factor VII.

ISSN: 1364-8535